兩階段適應性無縫設計改良-於劑量選擇後加入一新試驗組之調整

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：40

、訪客IP：18.119.106.134

姓名

吳緯綸(Wei-Lun Wu) 查詢紙本館藏

畢業系所

統計研究所

論文名稱

兩階段適應性無縫設計改良-於劑量選擇後加入一新試驗組之調整

相關論文

★ 長期與存活資料之聯合模型-新方法和數值方法的改進	★ 復發事件存活分析的共享廣義伽瑪脆弱因子之半母數聯合模型
★ 加乘法風險模型結合長期追蹤資料之聯合模型	★ 有序雙重事件時間分析使用與時間相關的共變數－邊際方法的比較
★ 存活與長期追蹤資料之聯合模型－台灣愛滋病實例研究	★ 以聯合模型探討地中海果蠅繁殖力與老化之關係
★ 聯合模型在雞尾酒療法療效評估之應用—利用CD4/CD8比值探討台灣愛滋病資料	★ 時間相依共變數之雙重存活時間分析—台灣愛滋病病患存活時間與 CD4 / CD8 比值關係之案例研究
★ Cox比例風險模型之參數估計─比較部分概似法與聯合模型	★ 復發事件存活時間分析-丙型干擾素對慢性肉芽病患復發療效之案例研究
★ Cox 比例風險假設之探討與擴充風險模型之應用	★ 以聯合模型探討原發性膽汁性肝硬化
★ 聯合長期追蹤與存活資料分析－肝硬化病患之實例研究	★ 復發事件存活時間分析-rhDNase對囊狀纖維化病患復發療效之案例研究
★ 聯合長期追蹤與存活資料分析-原發性膽汁性肝硬化病患之實例研究	★ 復發事件存活時間分析-Thiotepa對膀胱癌病患復發療效之案例研究

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

在臨床試驗的發展中，適應性無縫設計包含兩個階段，學習階段（二期階段）選擇劑量或試驗組，確認階段（三期階段）確認所選劑量或試驗組的治療效果。由於在一個方案中結合傳統的二三期試驗，以至於有可能可以縮短新藥開發所需要的時間而備受製藥公司關注。本研究提出一個除了在二期階段結束時，基於短期終點選擇一個試驗組外，並增加一個新的試驗組在三期階段的無縫設計。在最終分析時，利用封閉檢定法控制由於劑量選擇造成可能的總體型一錯誤率膨脹，另外使用逆常態加權組合函數結合兩階段基於入組受試者晚期終點所得到p值以進行統計推論。本研究提出依序檢定與同時檢定兩種檢定策略，依序檢定首先檢定二期階段選出的試驗組，若達顯著則再檢定新增的試驗組；同時檢定則同時檢定兩個試驗組。本研究透過大量的模擬，以驗證此設計在不同情境下能控制總體型一錯誤率並達到足夠的檢定力。

摘要(英)

In the development of clinical trial design, adaptive seamless design contains learning stage and confirmatory stage corresponding to conventional phase Ⅱ/Ⅲ trial respectively. Typically, experimental groups as doses of test drug or treatment groups compared to an active control are evaluated at the learning stage, based on the results of the learning stage, the efficacy of selected dose or treatment group is to be confirmed at the confirmatory stage. As adaptive seamless design combines conventional phase Ⅱ/Ⅲ trial into a trial design, it might shorten time needed to develop new drugs, which has drawn considerable attention from researchers and pharmaceutical companies. We proposed a seamless design which is able to select an experimental group at the end of learning stage based on short-term outcome and to add a new experimental group into confirmatory stage. The closed testing procedure and weighted inverse normal combination function are used to control the inflation of overall type I error rate due to dose selection and p-values from two stage subjects at the final analysis. We proposed sequentially and simultaneously testing strategy for testing the new experimental group. Sequentially testing strategy tests the selected experimental group first, if significant then test the new experimental group. Simultaneously testing strategy tests the selected and new experimental groups at the same time. Numerical simulation has been conducted to verify the type I error rate and power under several scenarios.

關鍵字(中)

★ 適應性設計
★ 無縫二三期設計
★ 封閉檢定法
★ 早期終點
★ 晚期終點
★ 逆常態加權組合函數

關鍵字(英)

★ adaptive design
★ seamless design
★ closed testing procedure
★ short-term outcome
★ long-term outcome
★ weighted inverse normal combination function

論文目次

內容
摘要 i
Abstract ii
致謝 iii
圖目錄 vi
表目錄 vii
一.緒論 1
1.1臨床試驗 2
1.2適應性設計 6
1.2.1 定義與目的 7
1.2.2 統計考量議題 8
1.2.3 常見適應性設計 11
1.3新生血管型老年性黃斑部病變與其治療發展 16
1.3.1疾病介紹 16
1.3.2 Verteporfin光動力療法 17
1.3.3 抗血管內皮生長因子療法 18
1.3.4 以雷珠單抗治療新生血管型老年性黃斑部病變之三篇關鍵性臨床試驗報告 19
1.4研究動機 24
二.兩階段適應性無縫設計 28
2.1 適應性無縫設計之發展 28
2.2 設計介紹 32
2.3 早期終點、主要終點、統計量計算 33
2.4 多重假設檢定與封閉檢定法 35
2.5 計算p值 37
2.5.1 Bonferroni 檢定 38
2.5.2 Sidak 檢定 39
2.5.3 Simes 檢定 40
2.5.4 適應性Dunnett 檢定 41
2.5.5 組合函數 42
2.5.6 敗者試驗組追蹤問題 43
三.兩階段適應性無縫設計改良-加入一新試驗組之調整 45
3.1 設計介紹 45
3.2 設計調整 46
3.2.1 新試驗組之主要終點 47
3.2.2 統計量計算 48
3.2.3 計算p值 48
四.模擬方法設計 55
4.1 R套件-asd介紹 55
4.2 asd中函數simeans.binormal、select.rule與dunnett.test介紹 59
4.3 模擬情境 64
4.4 應用套件asd內函數設計模擬方法 65
五. 樣本數計算 73
6. 模擬方法設計與模擬結果探討 75
6.1 模擬探討議題 75
6.2 型一錯誤率模擬 76
6.2.1 四種p值計算法在型一錯誤率表現上的比較 78
6.2.2 敗者試驗組處理對型一錯誤率影響 80
6.2.3 早期終點平均差異對型一錯誤率影響 81
6.2.4 四種p值計算法在早期終點平均有差異時的型一錯誤率表現 82
6.2.5 敗者試驗組處理在早期終點平均有差異時的型一錯誤率表現 83
6.2.6 不同的b值對型一錯誤率的影響 84
6.3 檢定力模擬 85
6.3.1 不同非劣性程度對檢定力影響 86
6.3.2 敗者試驗組處理對檢定力影響 88
6.3.3 早期終點平均差異對檢定力影響 89
6.3.4 敗者試驗組處理在早期終點平均有差異時的檢定力表現 90
6.3.5 不同b值的影響 91
6.3.6 新試驗組藥效較低的影響 92
6.4 模擬結果討論 93
7. 結論與討論 94
參考文獻 96
附錄 107
附錄一-使用Bonferroni、Sidak、Simes計算p值 107

參考文獻

Barkhof, F., Calabresi, P. A., Miller, D. H., & Reingold, S. C. (2009). Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nature Reviews Neurology, 5, 256–266.

Bauer, P., & Rohmel J. (1995). An adaptive method for establishing a dose-response relationship. Statistics in Medicine, 14, 1595-1607.

Bauer, P. (1989). Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie, 20, 130-148.

Bauer, P., & Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine, 18, 1833-1848.

Bauer, P., & Kohne, K. (1994). Evaluation of Experiments with Adaptive Interim Analyses. Biometrics, 50, 1029-1041.

Berg, K., Pedersen, T. R., Sandvik, L., & Bragadóttir, R. (2015). Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol. Ophthalmology, 122, 146-152.

Bermel, R. A., & Bakshi, R. (2006). The measurement and clinical relevance of brain atrophy in multiple sclerosis. The Lancet Neurology, 5, 158-170.

Biswas, P., Sengupta, S., Choudhary, R., Home, S., Paul, A., & Sinha, S. (2011). Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian Journal of Ophthalmology, 59(3), 191-196.

Bonferroni, C. E. (1936). Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze.

Brannath W, Koening F, & Bauer P. (2003). Improved repeated confidence bounds in trials with a maximal goal. Biometrical Journal, 45, 311-324.

Bretz, F., Koenig, F., Brannath, W., Glimm, E., & Posch, M. (2009). Adaptive designs for confirmatory clinical trials. Statistics in Medicine, 28(8), 1181-1217.

Bretz, F., Schmidli, H., König, F., Racine, A., & Maurer, W. (2006). Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts. Biometrical Journal, 48(4), 623-634.

Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009). Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology, 116(1), 57-65.

Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013). Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet, 382(9900), 1258-1267.

Chang, M., & Chow, S.-C. (2005). A Hybrid Bayesian Adaptive Design for Dose Response Trials. Journal of Biopharmaceutical Statistics, 15(4), 677-691.

Chow, S.-C., Chang, M., Pong, A. (2005). Statistical consideration of adaptive methods in clinical development. Journal of Biopharmaceutical Statistics, 15,575-591.

Chow, S.-C., & Chang, M. (2008). Adaptive design methods in clinical trials – a review. Orphanet Journal of Rare Diseases, 3(1), 3-11.

Chuang-Stein, C., Anderson, K., Gallo, P., & Collins, S. (2006). Sample Size Reestimation: A Review and Recommendations. Drug Information Journal, 40(4), 475-484.

Cui, L., Hung, H. M. J., & Wang, S.-J. (1999). Modification of Sample Size in Group Sequential Clinical Trials. Biometrics, 55(3), 853–857.

Efron, B. (1971). Forcing a sequential experiment to be balanced. Biometrika, 58,403-417.

FDA. (1997). E8 General Considerations for Clinical Trials.

FDA. (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.

Filippi, M., Rocca, M. A., Martino, G., Horsfield, M. A., & Comi, G. (1998). Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Annals of Neurology, 43(6), 809-814.

Follmann, D. A., Proschan, M. A., & Geller, N. L. (1994). Monitoring Pairwise Comparisons in Multi-Armed Clinical Trials. Biometrics, 50(2), 325-336.

Friede, T., & Kieser, M. (2004). Sample size recalculation for binary data in internal pilot study designs. Pharmaceutical Statistics, 3(4), 269-279.

Friede, T., Parsons, N., Stallard, N., Todd, S., Valdes Marquez, E., Chataway, J., Nicholas, R. (2011). Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Statistics in Medicine, 30, 1528-1540.

Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006). Adaptive Designs in Clinical Drug Development-An Executive Summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics, 16(3), 275-283.

Hardwick, J., & Stout, Q. F. (2002). Optimal few-stage designs. Journal of Statistical Planning and Inference, 104(1), 121-145.

Hellmich, M. (2001). Monitoring clinical trials with multiple arms. Biometrics, 57, 892-898.

Ho, T. W., Pearlman, E., Lewis, D., Hämäläinen, M., Connor, K., Michelson, D, Zhang, Y., Assaid, C., Mozley, L. H., Strickler N. Bachman R., Mahoney, E., Lines, C., Hewtt D. J. (2012). Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia, 32(10), 750-765.

James Hung, H. M., Cui, L., Wang, S.-J., & Lawrence, J. (2005). Adaptive Statistical Analysis Following Sample Size Modification Based on Interim Review of Effect Size. Journal of Biopharmaceutical Statistics, 15(4), 693-706.

Jennison, C., & Turnbull, B. W. (2005). Meta-Analyses and Adaptive Group Sequential Designs in the Clinical Development Process. Journal of Biopharmaceutical Statistics, 15(4), 537-558.

Jennison, C., & Turnbull, B. W. (1999). Group Sequential Methods with Applications to Clinical Trials. CRC Press

Kelly, P. J., Stallard, N., & Todd, S. (2005). An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several. Journal of Biopharmaceutical Statistics, 15(4), 641-658.

Kodjikian, L., Souied, E. H., Mimoun, G., Mauget-Faÿsse, M., Behar-Cohen, F., Decullier, E., & Aulagner, G. (2013). Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology, 120(11), 2300-2309.

Koenig, F., Brannath, W., Bretz, F., & Posch, M. (2008). Adaptive Dunnett tests for treatment selection. Statistics in Medicine, 27(10), 1612-1625

Krebs, I., Schmetterer, L., Boltz, A., Told, R., Vécsei-Marlovits, V., & Egger, S. (2013). A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. British Journal of Ophthalmology, 97(3), 266-271.

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444-1444.

Kwon, O.W., Lee,F. L., Chung H., Lai, C. C., Sheu S. J., & Yoon, Y. H. (2012). EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefes Arch Clin Exp Ophthalmol 250, 1467-1476.

Lachin, J. M. (1988). Statistical properties of randomization in clinical trials. Controlled Clinical Trials, 9(4), 289-311.

Lan, K. K. G., & Demets, D. L. (1989). Group sequential procedures: Calendar versus information time. Statistics in Medicine, 8(10), 1191-1198.

Lehmacher, W., & Wassmer, G. (1999). Adaptive Sample Size Calculations in Group Sequential Trials. Biometrics, 55, 1286-1290.

Liu, Q., & Chi, G. Y. H. (2001). On sample size and inference for two-stage adaptive designs. Biometrics, 57, 172-177.

Liu, Q., & Proschan, M.A., & Pledger, G. W. (2002). A unified theory of two-stage adaptive designs. Journal of American Statistical Association, 97, 1034-1041.

Maca, J., Bhattacharya, S., Dragalin, V., Gallo, P., & Krams, M. (2006). Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples. Drug Information Journal, 40(4), 463-473.

Magnusson, B. P., & Turnbull, B. W. (2013). Group sequential enrichment design incorporating subgroup selection. Statistics in Medicine, 32(16), 2695-2714.

Marcus, R., Peritz, E., & Gabriel, K. R. (1976). On Closed Testing Procedures with Special Reference to Ordered Analysis of Variance. Biometrika, 63(3), 655-660

Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G. S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F.L. 3rd. (2012). Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology, 119(7), 1388-98.

Nguyen Duc, A., Heinzmann, D., Berge, C., & Wolbers, M. (2020). A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies. Pharmaceutical Statistics.

Nguyen, C. L., Oh, L. J., Wong, E., Wei, J., & Chilov, M. (2018). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmology, 18(1), 130-144.

Ondra, T., Jobjörnsson, S., Beckman, R. A., Burman, C.-F., König, F., Stallard, N., & Posch, M. (2017). Optimized adaptive enrichment designs. Statistical Methods in Medical Research, 0(0), 1-16.

O′Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trial in cancer. Biometrics, 46, 33-48.

O′Quigley, J., & Shen, L. (1996). Continual reassessment method: A likelihood approach. Biometrics, 52,673-684.

Parsons, N., Friede, T., Todd, S., Marquezd E. V., Chataway J., Nicholas R., Stallard N. (2012). An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis 56, 1150-1160.

Posch, M., Bauer, P. (1999). Adaptive two-satge designs and the conditional error function. Biometrical Journal, 41, 689-696.

Posch, M., Koenig, F., Branson, M., Brannatch, W., Dunger-Baldauf, C., & Bauer, P. (2005). Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine, 24, 3697-3714.

Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics, 51, 1315-1324.

Proschan, M. A. (2005). Two-stage sample size re-estimation based on a nuisance parameter: a review. Journal of Biopharmaceutical Statistics, 15, 539-574.

Rosenberger, W. F., Stallard, N., Ivanova, A., Harper, C. N., & Ricks, M. L. (2001). Optimal adaptive designs for binary response trials. Biometrics, 57, 909-913.

Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y., Group ftMS. (2006). Ranibizumab for Neovascular age-related macular degeneration. N Engl J Med. 355(14), 1419-31.

Sampson, A. R., & Sill, M. W. (2005). Drop-the-loser design: normal case (with discussions). Biometrical Journal, 47, 257-281.

Sarkar, S. K., & Chang, C.-K. (1997). The Simes Method for Multiple Hypothesis Testing with Positively Dependent Test Statistics. Journal of the American Statistical Association, 92(440), 1601-1608.

Schauwvlieghe, AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. (2016). Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One, 11(5), e0153052.

Schmidli, H., Bretz, F., Racine, A., & Maurer, W. (2006). Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations. Biometrical Journal, 48(4), 635-643.

Shi, Q., Pavey, E. S., & Carter, R. E. (2012). Bonferroni-based correction factor for multiple, correlated endpoints. Pharmaceutical Statistics, 11(4), 300-309.

Shih, W. J. (2006). Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison. Statistics in Medicine, 25, 933-941.

Šidák, Z. (1967). Rectangular Confidence Regions for the Means of Multivariate Normal Distributions. Journal of the American Statistical Association, 62(318), 626-633.

Simes, R. J. (1986). An Improved Bonferroni Procedure for Multiple Tests of Significance. Biometrika, 73(3), 751-754.

Subramanian, M. L., Abedi, G., Ness, S., Ahmed, E., Fenberg, M., Daly, M. K., Feinberg, E. B. (2010). Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye, 24(11), 1708-1715.

Tano, Y. & Ohji, M. (2010). EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol, 88, 309-316.

Wang, S. K., & Tsiatis, A. A. (1987). Approximately Optimal One-Parameter Boundaries for Group Sequential Trials. Biometrics, 43(1), 193-199.

Wang, S.-J., James Hung, H. M., & O’Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal, 51(2), 358-374.

Wassmer, G., & Brannath, W. (2016). Group Sequential and Confirmatory Adaptive Designs in Clinical Trials. Springer Series in Pharmaceutical Statistics.

Whitehead J. (1997). Bayesian decision procedures with application to dose-finding studies. International Journal of Pharmaceutical Medicine, 11, 201-208.

Woodcock J. (2005). FDA introduction comments: clinical studies design and evaluation issues. Clinical Trials, 2, 273-275.

Zhang, W., Sargent, D. J., & Mandrekar, S. (2006). An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine, 25(14), 2365-2383.

Zhao, J., Li, X., Tang, S., Xu, G., Xu, X., Zhang, F., & Nieweg, A. (2014). EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. BioDrugs, 28(6), 527-536.

指導教授

曾議寬

審核日期

2021-7-21

推文